Digital Technologies to Address the Social Determinants of Health in Context of Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional) | RFA DA 21 032

Opportunity Information: Apply for RFA DA 21 032

The National Institutes of Health (NIH) released this Small Business Innovation Research (SBIR) funding opportunity, RFA-DA-21-032, titled "Digital Technologies to Address the Social Determinants of Health in Context of Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional)." It is a discretionary grant program in the health arena (CFDA 93.279) designed specifically for small businesses that can build commercially viable digital health products. The central aim is to support research and development of digital technologies that can improve outcomes for people affected by substance use disorders, including opioid use, by targeting the social and environmental conditions that increase risk or make recovery harder.

A key feature of this opportunity is its focus on the social determinants of health (SDOH). Rather than concentrating only on clinical treatment or medication adherence, the announcement emphasizes interventions that address upstream factors like housing instability, unemployment and income insecurity, lack of transportation, food insecurity, limited access to supportive services, social isolation, exposure to violence, involvement with the justice system, and other community or structural barriers. The underlying idea is that even strong clinical care can fall short if people cannot reliably access services, maintain stable living conditions, or navigate complex systems; digital tools may help close those gaps in practical, scalable ways.

The funded work is expected to produce "commercializable" digital health-based products. In practice, that implies applicants should be developing something that could realistically be brought to market and adopted in real-world settings such as community organizations, treatment programs, primary care practices, recovery support services, public health agencies, or justice-related settings. The product could take many forms, including mobile apps, web platforms, telehealth enhancements, care coordination tools, decision-support systems, remote monitoring approaches, digital navigation and referral tools, or other software-driven solutions. The emphasis is not just on technology for its own sake, but technology that measurably improves SDOH-related risks and supports people who use drugs or are in recovery.

This is an R43/R44 opportunity, meaning it follows the SBIR phased structure: Phase I (R43) typically supports early feasibility, prototype development, and proof-of-concept work, while Phase II (R44) generally supports more advanced development, refinement, and evaluation steps that move the product toward commercialization. The "Clinical Trial Optional" label signals that applicants may propose studies that include clinical trial elements, but they are not required to do so. In other words, proposals could range from formative research and user-centered design through pilot testing and broader effectiveness evaluations, depending on what is appropriate for the maturity of the product and the research questions.

Eligibility is limited to small businesses, consistent with SBIR requirements. The announcement also states clear restrictions related to foreign participation: non-U.S. entities (foreign institutions) are not eligible to apply, and non-U.S. components of U.S. organizations are not eligible to apply. However, "foreign components" as defined in the NIH Grants Policy Statement may be allowed, which typically means certain project elements could occur outside the U.S. under specific NIH rules and prior approval, but the applicant organization itself must be a U.S. small business and must comply with NIH policies on foreign involvement.

Administratively, the opportunity was created on December 22, 2020, with an original closing date of February 26, 2021. The sponsoring agency is NIH, and while the provided source text does not list an award ceiling or the number of expected awards, applicants would normally look to the full FOA and NIH SBIR policy guidance for budget limits, project periods, and review considerations.

Overall, this grant opportunity is aimed at helping small businesses translate innovative digital health ideas into practical tools that address real-life conditions shaping SUD risk and recovery. The strongest projects would typically be those that show a clear understanding of the target population and setting, demonstrate a plausible pathway to adoption and scale, and propose a development and evaluation plan that ties the digital solution directly to measurable improvements in social determinants that matter for substance use outcomes.

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Digital Technologies to Address the Social Determinants of Health in Context of Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279.
• This funding opportunity was created on 2020-12-22.
• Applicants must submit their applications by 2021-02-26. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: Small businesses.

Apply for RFA DA 21 032

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: